About
Tolemy Bio is a biotech startup developing Orbit, an AI-native platform designed to help researchers better understand, interpret, and optimize living cells for modern therapies and drug development. The platform aims to address the fragmentation and manual nature of current experimental workflows by connecting existing lab tools and data sources, incorporating virtual cell models, and utilizing AI research agents for analysis and decision-making. Their long-term goal is to build a virtual-cell platform that enables more precise and data-driven approaches to cell biology research and biopharma development.
Key facts
At-a-glance profile data
- Website
- tolemybio.com
- Headquarters
- Cambridge, England, United Kingdom
- Founded
- 2022
- Employees
- 4
- Total funding
- $1M (Pre-Seed)
- Business model
- B2B
Funding rounds
| Date | Round | Amount | Lead investors |
|---|---|---|---|
| 12 May 2026 | Pre-Seed | $1M | Norrsken Evolve |
Frequently asked
How much funding has Tolemy Bio raised?
Tolemy Bio has raised a total of $1M in funding. The most recent round on record is Pre-Seed.
How many employees does Tolemy Bio have?
Tolemy Bio has approximately 4 people on record.
What is Tolemy Bio's current status?
Tolemy Bio's current operating status is: Inactive.